Seeking Alpha

Cantor Fitzgerald initiates Verastem (VSTM) at Buy with a $22 price target noting the company's...

Cantor Fitzgerald initiates Verastem (VSTM) at Buy with a $22 price target noting the company's "scientific and executive founders are a virtual panoply of who's who in cancer stem cell research." Furthermore, analyst Mara Goldstein says the company has a "compelling mix" of other catalysts and VS-6063 (previous) may have applications outside of mesothelioma.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|